AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

AbbVie and Roche’s Venclexta is leaving familiar territory with its latest approval, and it won’t be an easy land grab. To establish itself on its new turf, the blood cancer drug will have to duke it out with some Big Pharma rivals.